PL446349A1 - Przeciwciała bispecyficzne anty-AXL i anty-PD-L1 oraz ich zastosowanie w terapii, zwłaszcza w leczeniu nowotworu - Google Patents

Przeciwciała bispecyficzne anty-AXL i anty-PD-L1 oraz ich zastosowanie w terapii, zwłaszcza w leczeniu nowotworu

Info

Publication number
PL446349A1
PL446349A1 PL446349A PL44634923A PL446349A1 PL 446349 A1 PL446349 A1 PL 446349A1 PL 446349 A PL446349 A PL 446349A PL 44634923 A PL44634923 A PL 44634923A PL 446349 A1 PL446349 A1 PL 446349A1
Authority
PL
Poland
Prior art keywords
axl
bispecific antibody
antigen
antigen binding
therapy
Prior art date
Application number
PL446349A
Other languages
English (en)
Inventor
Olga ABRAMCZYK
Aleksandra Sowińska
Krzysztof LACEK
Damian KOŁAKOWSKI
Delfina POPIEL
Filip MITUŁA
Agnieszka BOJKO-MATUSZEK
Magdalena BOJKO
Maciej Wieczorek
Jerzy Pieczykolan
Original Assignee
Celon Pharma Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma Spółka Akcyjna filed Critical Celon Pharma Spółka Akcyjna
Priority to PL446349A priority Critical patent/PL446349A1/pl
Priority to PCT/PL2024/050076 priority patent/WO2025080151A1/en
Priority to AU2024359272A priority patent/AU2024359272A1/en
Publication of PL446349A1 publication Critical patent/PL446349A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Przedmiotem niniejszego zgłoszenia jest przeciwciało bispecyficzne zawierające jedną lub więcej domen wiążących antygen wiążących się specyficznie z antygenem AXL oraz jedną lub więcej domen wiążących antygen wiążących się specyficznie z antygenem PD-L1, którego wiązanie z antygenem AXL i/lub PD-L1 prowadzi do jego internalizacji, jak również jego fragment wiążący antygen wiążący się specyficznie z AXL i/lub PD-L1. Przedmiotem niniejszego zgłoszenia jest także kwas nukleinowy kodujący takie przeciwciało bispecyficzne lub jego fragment wiążący antygen, koniugat przeciwciało-lek zawierający takie przeciwciało bispecyficzne lub jego fragment wiążący antygen oraz kompozycja farmaceutyczna zawierająca takie przeciwciało bispecyficzne lub jego fragment wiążący antygen lub taki koniugat przeciwciało-lek oraz farmaceutycznie dopuszczalną zaróbkę lub nośnik. Przedmiotem niniejszego zgłoszenia jest ponadto takie przeciwciało bispecyficzne lub taki koniugat lub taka kompozycja farmaceutyczna do zastosowania w terapii, do zastosowania w terapii nowotworu, zwłaszcza nowotworu złośliwego, w szczególności nowotworu wykazującego ekspresję powierzchniową AXL i/lub PD-L1 Przedmiotem zgłoszenia jest również sposób leczenia lub zapobiegania nowotworowi lub jego przerzutowaniu u osobnika oraz sposób stymulowania odpowiedzi immunologicznej, obejmujące podawanie takiego przeciwciała bispecyficznego, takiego jego fragmentu, koniugatu lub kompozycji farmaceutycznej osobnikowi.
PL446349A 2023-10-11 2023-10-11 Przeciwciała bispecyficzne anty-AXL i anty-PD-L1 oraz ich zastosowanie w terapii, zwłaszcza w leczeniu nowotworu PL446349A1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL446349A PL446349A1 (pl) 2023-10-11 2023-10-11 Przeciwciała bispecyficzne anty-AXL i anty-PD-L1 oraz ich zastosowanie w terapii, zwłaszcza w leczeniu nowotworu
PCT/PL2024/050076 WO2025080151A1 (en) 2023-10-11 2024-10-10 Bispecific anti-axl and anti-pd-l1 antibodies and their use in therapy, particularly in the treatment of neoplasm
AU2024359272A AU2024359272A1 (en) 2023-10-11 2024-10-10 Bispecific anti-axl and anti-pd-l1 antibodies and their use in therapy, particularly in the treatment of neoplasm

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL446349A PL446349A1 (pl) 2023-10-11 2023-10-11 Przeciwciała bispecyficzne anty-AXL i anty-PD-L1 oraz ich zastosowanie w terapii, zwłaszcza w leczeniu nowotworu

Publications (1)

Publication Number Publication Date
PL446349A1 true PL446349A1 (pl) 2025-04-14

Family

ID=93939551

Family Applications (1)

Application Number Title Priority Date Filing Date
PL446349A PL446349A1 (pl) 2023-10-11 2023-10-11 Przeciwciała bispecyficzne anty-AXL i anty-PD-L1 oraz ich zastosowanie w terapii, zwłaszcza w leczeniu nowotworu

Country Status (3)

Country Link
AU (1) AU2024359272A1 (pl)
PL (1) PL446349A1 (pl)
WO (1) WO2025080151A1 (pl)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016005593A1 (en) * 2014-07-11 2016-01-14 Genmab A/S Antibodies binding axl
WO2020259566A1 (zh) * 2019-06-27 2020-12-30 启愈生物技术(上海)有限公司 抗PD-L1纳米抗体及其Fc融合蛋白和应用
WO2021115456A1 (en) * 2019-12-11 2021-06-17 Wuxi Biologics (Shanghai) Co., Ltd. BI-FUNCTIONAL ANTIBODY AGAINST PD-L1 AND TGFβ
WO2023126932A1 (en) * 2021-12-30 2023-07-06 B.G. Negev Technologies And Applications Ltd., At Ben-Gurion University Antibody conjugates for the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202002331QA (en) * 2017-09-13 2020-04-29 Nat Res Council Canada Axl-specific antibodies and uses thereof
EP4355786A1 (en) * 2021-06-16 2024-04-24 Alector LLC Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
CN116731188B (zh) * 2022-03-02 2025-02-14 三优生物医药(上海)有限公司 抗pd-l1和vegf双特异性抗体及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016005593A1 (en) * 2014-07-11 2016-01-14 Genmab A/S Antibodies binding axl
WO2020259566A1 (zh) * 2019-06-27 2020-12-30 启愈生物技术(上海)有限公司 抗PD-L1纳米抗体及其Fc融合蛋白和应用
WO2021115456A1 (en) * 2019-12-11 2021-06-17 Wuxi Biologics (Shanghai) Co., Ltd. BI-FUNCTIONAL ANTIBODY AGAINST PD-L1 AND TGFβ
WO2023126932A1 (en) * 2021-12-30 2023-07-06 B.G. Negev Technologies And Applications Ltd., At Ben-Gurion University Antibody conjugates for the treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALVARADO D ET AL.: "J. ImmunoTherapy of Cancer 2020, 8, A334.1.", 550 AN AXL-TARGETING MONOCLONAL ANTIBODY THAT INHIBITS AXL ACTIVITY AND POTENTLY STIMULATES THE INNATE IMMUNE RESPONSE. *

Also Published As

Publication number Publication date
AU2024359272A1 (en) 2026-03-26
WO2025080151A1 (en) 2025-04-17

Similar Documents

Publication Publication Date Title
PH12019502484A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
GEAP202416114A (en) Antibody drug conjugate, preparation method therefor and use thereof
MX2021011500A (es) Anticuerpos multiespecificos egfr x cd28.
MX2024013016A (es) Anticuerpos anti-pd1 para usarse en el tratamiento del cancer
MY199468A (en) Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
WO2021227307A8 (zh) 抗cd73抗体及其用途
JOP20220070A1 (ar) مترافقات جسم مضاد- عقار مضاد لميزوثيلين إيريبولين وطرق استخدامها
ZA201907225B (en) Treatment of her2 positive cancers
MX2023014069A (es) Composiciones y métodos para el tratamiento del cáncer de próstata.
CY1113287T1 (el) Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα
ZA202006504B (en) Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof
MX2024006743A (es) Unidad de union a antigeno ccr8 y usos de los mismos.
ZA202302392B (en) Antibodies against ilt2 and use thereof
MX2025006057A (es) Conjugados anticuerpo-farmaco anti-cea y metodos de uso
MX2022015375A (es) Conjugados de farmaco-anticuerpo anti-factor de tejido y su uso en el tratamiento de cancer.
MX2025007664A (es) Conjugados de anticuerpos farmacos b7h3
MX2025010185A (es) Conjugados anticuerpo-farmaco administrados por via subcutanea para el uso en el tratamiento del cancer
WO2022238963A3 (en) Genetically engineered immune cells targeting cd70 for use in treating solid tumors
MX2024007035A (es) Anticuerpos anti-cdh6 y conjugados anticuerpo-farmaco de los mismos.
MX2025004144A (es) Anticuerpo anti-gucy2c y usos del mismo
MX2025001452A (es) Anticuerpos anti-ccr8 y metodos de uso
MX2025004652A (es) Conjugados de farmaco-anticuerpo del cumulo de diferenciacion (cd70) y metodos de uso de los mismos
MX2022006728A (es) Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario.
ATE461713T1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
PL446349A1 (pl) Przeciwciała bispecyficzne anty-AXL i anty-PD-L1 oraz ich zastosowanie w terapii, zwłaszcza w leczeniu nowotworu